Gilead's Epclusa And Merck's Zepatier Hep C Combos Get EMA backing

Gilead's sofosbuvir/velpatasvir combination Epclusa and Merck's grazoprevir and elbasvir combo Zepatier are on course for approval in Europe for treating hepatitis C, but analysts say Gilead's two-drug therapy has the better commercial prospects of the two.